Effects of two different dexamethasone dosing regimens on ventilator-free days and long ...
The REMED trial was a multicenter, randomized, open-label study in Czech Republic evaluating dexamethasone in COVID-19 ARDS patients. It included 222 patients, randomized 1:1 to receive high-dose (20 mg/day for 5 days, then 10 mg/day for 5 days) or standard-dose (6 mg/day for 10 days) dexamethasone. Primary outcome was ventilator-free days at day 28. Recruitment ended early due to futility, with 69.6% power to detect a 3 VFD difference.
Highlighted Terms
Related News
The REMED trial was a multicenter, randomized, open-label study in Czech Republic evaluating dexamethasone in COVID-19 ARDS patients. It included 222 patients, randomized 1:1 to receive high-dose (20 mg/day for 5 days, then 10 mg/day for 5 days) or standard-dose (6 mg/day for 10 days) dexamethasone. Primary outcome was ventilator-free days at day 28. Recruitment ended early due to futility, with 69.6% power to detect a 3 VFD difference.